ReGenTree

Executive Summary

ReGenTree is a San Diego-based private biotechnology company founded in 2014, dedicated to developing novel therapies for ophthalmic disorders using the regenerative protein Thymosin β4 (Tβ4). The company's pipeline targets serious eye diseases, including dry eye syndrome and neurotrophic keratopathy, leveraging Tβ4's anti-inflammatory and wound-healing properties. By focusing on unmet medical needs in ophthalmology, ReGenTree aims to become a global leader in this niche therapeutic area. The company's platform has the potential to address millions of patients suffering from chronic ocular surface conditions, offering a differentiated mechanism of action compared to existing treatments. As a privately held firm, ReGenTree's progress is closely tied to clinical development milestones and strategic partnerships. The company has not yet disclosed detailed pipeline stages or funding rounds, suggesting a relatively early development phase. However, the strong scientific rationale behind Tβ4 and the significant market opportunity in ophthalmology provide a favorable outlook. Key upcoming catalysts include clinical data readouts, regulatory interactions, and potential collaboration agreements. The company's success hinges on demonstrating clinical efficacy and safety in its lead indications, as well as securing adequate capital to advance its programs.

Upcoming Catalysts (preview)

• Q3 2026Phase 2/3 data readout for dry eye syndrome candidate40% success
• Q4 2026FDA IND clearance or meeting for neurotrophic keratopathy program30% success
• TBDStrategic partnership or licensing deal for Tβ4 platform20% success